The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Giovanni Barosi

Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis

IRCCS Policlinico S. Matteo Foundation

Viale Golgi 19

27100 Pavia

Italy

[email]@smatteo.pv.it

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Unit of Clinical Epidemiology and Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Viale Golgi 19, 27100 Pavia, Italy. 1999 - 2012
  • Laboratory of Clinical Epidemiology, IRCCS Policlinico S.Matteo, Pavia, Italy. 1999 - 2006
  • Unit of Clinical Epidemiology, IRCCS Policlinico S. Matteo, Pavia and Second Division of Hematology, Ospedale San Martino, Italy. 2006
  • Laboratory of Medical Informatics, the Unit of Clinical Immunology and Immunohematology, the Transfusion Service, Policlinico San Matteo, Italy. 2001

References

  1. Emerging targeted therapies in myelofibrosis. Barosi, G. Expert. Rev. Hematol (2012) [Pubmed]
  2. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Barosi, G., Merlini, G., Billio, A., Boccadoro, M., Corradini, P., Marchetti, M., Massaia, M., Tosi, P., Palumbo, A., Cavo, M., Tura, S. Ann. Hematol. (2012) [Pubmed]
  3. Management of myeloproliferative neoplasms: from academic guidelines to clinical practice. Barosi, G., Lupo, L., Rosti, V. Curr. Hematol. Malig. Rep (2012) [Pubmed]
  4. Therapeutic approaches in myelofibrosis. Barosi, G., Rosti, V., Vannucchi, A.M. Expert. Opin. Pharmacother (2011) [Pubmed]
  5. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Barosi, G., Birgegard, G., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Kiladjian, J.J., Lengfelder, E., McMullin, M.F., Passamonti, F., Reilly, J.T., Vannucchi, A.M., Barbui, T. Blood (2009) [Pubmed]
  6. Novel strategies for patients with chronic myeloproliferative disorders. Barosi, G., Rosti, V. Curr. Opin. Hematol. (2009) [Pubmed]
  7. New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia. Barosi, G. Eur. J. Haematol. Suppl (2007) [Pubmed]
  8. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Barosi, G., Bergamaschi, G., Marchetti, M., Vannucchi, A.M., Guglielmelli, P., Antonioli, E., Massa, M., Rosti, V., Campanelli, R., Villani, L., Viarengo, G., Gattoni, E., Gerli, G., Specchia, G., Tinelli, C., Rambaldi, A., Barbui, T. Blood (2007) [Pubmed]
  9. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Barosi, G., Besses, C., Birgegard, G., Briere, J., Cervantes, F., Finazzi, G., Gisslinger, H., Griesshammer, M., Gugliotta, L., Harrison, C., Hasselbalch, H., Lengfelder, E., Reilly, J.T., Michiels, J.J., Barbui, T. Leukemia (2007) [Pubmed]
  10. Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Barosi, G., Carella, A., Lazzarino, M., Marchetti, M., Martelli, M., Rambaldi, A., Tarella, C., Vitolo, U., Zinzani, P.L., Tura, S. Haematologica (2006) [Pubmed]
  11. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Barosi, G., Bacigalupo, A. Curr. Opin. Hematol. (2006) [Pubmed]
  12. Strategies for dissemination and implementation of guidelines. Barosi, G. Neurol. Sci. (2006) [Pubmed]
  13. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Barosi, G., Bordessoule, D., Briere, J., Cervantes, F., Demory, J.L., Dupriez, B., Gisslinger, H., Griesshammer, M., Hasselbalch, H., Kusec, R., Le Bousse-Kerdiles, M.C., Liberato, N.L., Marchetti, M., Reilly, J.T., Thiele, J. Blood (2005) [Pubmed]
  14. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Barosi, G., Carella, A., Lazzarino, M., Marchetti, M., Martelli, M., Rambaldi, A., Tarella, C., Vitolo, U., Zinzani, P.L., Tura, S. Haematologica (2005) [Pubmed]
  15. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Barosi, G., Rosti, V., Massa, M., Viarengo, G.L., Pecci, A., Necchi, V., Ramaioli, I., Campanelli, R., Marchetti, M., Bazzan, M., Magrini, U. Br. J. Haematol. (2004) [Pubmed]
  16. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Barosi, G., Boccadoro, M., Cavo, M., Corradini, P., Marchetti, M., Massaia, M., Merlini, G., Tosi, P., Tura, S. Haematologica (2004) [Pubmed]
  17. Myelofibrosis with myeloid metaplasia. Barosi, G. Hematol. Oncol. Clin. North Am. (2003) [Pubmed]
  18. High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy. Barosi, G., Salvaneschi, L., Grasso, M., Martinetti, M., Marchetti, M., Bodini, U., Reggiani, A., D'Agostino, F., Nalli, G., Degiuli, A., De Silvestri, A., Arbustini, E. Haematologica (2002) [Pubmed]
  19. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies. Barosi, G., Giovanni, B., Elliott, M., Michelle, E., Canepa, L., Letizia, C., Ballerini, F., Filippo, B., Piccaluga, P.P., Pier Paolo, P., Visani, G., Giuseppe, V., Marchetti, M., Monia, M., Pozzato, G., Gabriele, P., Zorat, F., Francesca, Z., Tefferi, A., Ayalew, T. Leuk. Lymphoma (2002) [Pubmed]
  20. Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Barosi, G., Grossi, A., Comotti, B., Musto, P., Gamba, G., Marchetti, M. Br. J. Haematol. (2001) [Pubmed]
  21. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Barosi, G., Viarengo, G., Pecci, A., Rosti, V., Piaggio, G., Marchetti, M., Frassoni, F. Blood (2001) [Pubmed]
  22. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Barosi, G., Ambrosetti, A., Finelli, C., Grossi, A., Leoni, P., Liberato, N.L., Petti, M.C., Pogliani, E., Ricetti, M., Rupoli, S., Visani, G., Tura, S. Br. J. Haematol. (1999) [Pubmed]
  23. Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines. Barosi, G. J. Clin. Oncol. (1999) [Pubmed]
 
WikiGenes - Universities